Yusen Logistics Benelux Belgium

Yusen Logistics Benelux Belgium is a subsidiary of Yusen Logistics (Benelux) B.V., a logistics and supply chain management company headquartered in Moerdijk, Netherlands. (craft.co) The company specializes in providing comprehensive logistics services, including air and ocean freight forwarding, warehousing, distribution, and supply chain management. In Belgium, Yusen Logistics operates as a third-party logistics (3PL) provider, focusing on the pharmaceutical and healthcare sectors. The Belgian branch is located at Keetberglaan 2, 9120 Melsele, Belgium. (trendstop.knack.be)

Yusen Logistics Benelux is part of the global Yusen Logistics network, which is a subsidiary of Nippon Yusen Kabushiki Kaisha (NYK Line), one of the world's largest shipping companies. (craft.co) The company plays a significant role in Belgium's pharmaceutical supply chain by offering specialized logistics services tailored to the needs of pharmaceutical companies. This includes the importation and distribution of finished pharmaceutical formulations, as evidenced by TransData Nexus proprietary trade data indicating that Yusen Logistics Benelux Belgium imported $279.0 million USD worth of finished pharmaceutical products from India between 2022 and 2026.

Yusen Logistics Benelux operates multiple warehouse facilities in Belgium to support its logistics operations. Notably, the company has a facility in Melsele, near Antwerp, which was expanded in July 2020 to include a new warehouse offering space for up to 15,000 pallets over nearly 5,000 square meters at a height of 17 meters. Additionally, in June 2024, Yusen Logistics, in collaboration with MG Real Estate and GSK, inaugurated a new 40,000 square meter pharmaceutical warehouse in Gembloux, Wallonia. This facility is the largest biopharmaceutical logistics center in Wallonia and features advanced technologies such as automated mobile robots and automated packaging systems. (mgrealestate.eu)

Yusen Logistics Benelux Belgium serves as a critical logistics intermediary within Belgium's pharmaceutical supply chain. The company's role encompasses the importation, storage, and distribution of finished pharmaceutical products, ensuring that these products are efficiently and safely delivered to various stakeholders, including wholesalers, hospitals, and pharmacies. The company's significant import activities, particularly from Indian pharmaceutical manufacturers, highlight its pivotal position in facilitating the availability of a diverse range of pharmaceutical products in the Belgian market.

Yusen Logistics Benelux Belgium's import data from India between 2022 and 2026 indicates a significant reliance on a single supplier. Out of a total import value of $279.0 million USD across 7,629 shipments, a substantial $238.7 million (approximately 85.6%) was sourced from SUN PHARMACEUTICAL INDUSTRIES LIMITED, accounting for 9,651 shipments. An additional $8.4 million (3.0%) came from SUN PHARMACEUTICAL INDUSTRIES LTD, with 349 shipments. This results in a combined supplier concentration of 88.6% from these two entities, leaving only 11.4% of imports diversified among other suppliers.

Such a high level of supplier concentration poses potential risks. While a strong relationship with a primary supplier can ensure consistent quality and streamlined operations, over-reliance on a single source may expose the company to supply disruptions due to unforeseen events affecting the supplier. Additionally, this dependency can diminish Yusen Logistics' negotiating leverage, potentially leading to less favorable pricing and terms. Industry benchmarks suggest that for non-specialized categories, a Herfindahl-Hirschman Index (HHI) below 1,500 indicates low concentration, while above 2,500 signifies high concentration. In this context, Yusen's supplier concentration would likely fall into the high category, indicating a need for diversification to mitigate associated risks.

The resilience of Yusen Logistics Benelux Belgium's supply chain is currently compromised due to its heavy dependence on a single supplier. The absence of a robust backup supplier strategy means that any disruption affecting SUN PHARMACEUTICAL INDUSTRIES LIMITED could significantly impact Yusen's ability to meet market demands. While the company imports a diverse range of 42 products across 12 therapeutic categories, the lack of supplier diversification undermines the overall resilience of the supply chain.

To enhance supply chain resilience, it is advisable for Yusen Logistics to establish relationships with additional suppliers, particularly those in different geographic regions. This geographic diversification can mitigate risks associated with regional disruptions. Furthermore, ensuring that all suppliers comply with regulatory standards, such as those set by the European Medicines Agency (EMA), is crucial to maintain product quality and regulatory compliance.

The current sourcing pattern places Yusen Logistics Benelux Belgium in a vulnerable position regarding supply security and negotiating power. The heavy reliance on a single supplier limits the company's ability to negotiate favorable terms and exposes it to potential supply chain disruptions. Diversifying the supplier base would not only mitigate these risks but also enhance the company's competitive position by ensuring a more stable and flexible supply chain.

For Indian exporters seeking to become alternative suppliers, this presents an opportunity to engage with Yusen Logistics. By offering competitive pricing, ensuring regulatory compliance, and demonstrating reliability, these exporters can position themselves as viable partners. This diversification would benefit both parties by reducing dependency risks and fostering a more resilient supply chain.

In Belgium, the Federal Agency for Medicines and Health Products (FAMHP) serves as the national regulatory authority overseeing the importation and distribution of pharmaceutical products. The primary legislation governing these activities includes the Royal Decree of 14 December 2006, which regulates medicinal products for human use.

For Indian generic pharmaceuticals to be marketed in Belgium, they must obtain a marketing authorization. This process involves submitting a comprehensive dossier to the FAMHP, detailing the product's quality, safety, and efficacy. The authorization can be pursued through national procedures or via the European Medicines Agency (EMA) for centralized approval, depending on the product's classification and intended market reach.

Importing pharmaceutical products into Belgium requires a Manufacturing and Import Authorization (MIA), which mandates compliance with Good Manufacturing Practice (GMP) standards. The EU recognizes GMP certificates from countries with Mutual Recognition Agreements (MRAs); however, India is not currently among these countries. Consequently, Indian manufacturing sites must undergo inspections by EU authorities to ensure GMP compliance. Additionally, entities involved in the wholesale distribution of pharmaceuticals must obtain a Wholesale Distribution Authorization (WDA) from the FAMHP, ensuring adherence to Good Distribution Practice (GDP) guidelines.

Each batch of imported pharmaceuticals must be certified by a Qualified Person (QP) within the EU before release to the market. This certification includes a full qualitative analysis, quantitative analysis of all active ingredients, and other necessary tests to confirm compliance with the marketing authorization. Labeling requirements in Belgium stipulate that information must be presented in the country's three official languages: Dutch, French, and German. Labels must include essential details such as the product name, dosage, method of administration, and any necessary warnings or precautions.

Several regulatory changes between 2024 and 2026 have impacted the importation of Indian pharmaceuticals into Belgium:

• September 2024: Belgium introduced a Royal Decree on 12 September 2024, effective from 1 November 2024, establishing import regimes for unlicensed medicines to address critical shortages. This decree allows for the importation of unlicensed medicines under specific conditions, potentially affecting the availability and distribution of certain pharmaceuticals.

• December 2025: The European Union reached a political agreement to modernize its pharmaceutical legislation, marking the most significant overhaul in over two decades. The new legislation aims to enhance access to medicines, streamline procedures, and foster innovation. The adopted acts are expected to enter into force in 2026, with a transition period until 2028 for member states to align their national laws. (ema.europa.eu)

• January 2026: Belgium updated its web portal 'Co-responsibility' on 14 January 2026 to enhance safety, harmonize GMP and GDP processes, and improve the traceability of inspection document archiving. This update aims to streamline regulatory processes and ensure compliance with GMP and GDP standards.

These regulatory developments underscore Belgium's commitment to ensuring the quality and safety of pharmaceutical imports, including those from India. Companies like Yusen Logistics Benelux Belgium, which imported finished pharmaceutical formulations valued at $279.0 million USD from India between 2022 and 2026, must stay abreast of these changes to maintain compliance and ensure uninterrupted market access.

Yusen Logistics Benelux Belgium's import data from India between 2022 and 2026 reveals a strategic focus on specific therapeutic areas. The top three categories—Gastrointestinal (24.3%), Vitamins & Supplements (19.0%), and Cardiovascular (16.2%)—account for nearly 60% of their imports. This concentration suggests a deliberate alignment with prevalent health concerns in Belgium, such as digestive disorders, nutritional deficiencies, and heart-related conditions. The emphasis on these categories indicates a response to substantial market demand, aiming to address common health issues within the population.

The prominence of products like Esomeprazole ($31.6M), Magnesium ($29.6M), and Omeprazole ($20.4M) further underscores this strategy. Esomeprazole and Omeprazole are widely used for treating acid reflux and related gastrointestinal conditions, while Magnesium supplements cater to nutritional needs. By prioritizing these products, Yusen Logistics demonstrates a commitment to supplying medications that are essential for managing prevalent health concerns in Belgium.

Yusen Logistics Benelux Belgium's procurement strategy heavily favors generic pharmaceuticals, as evidenced by their substantial imports from Indian suppliers. Notably, 96.6% of their imports, amounting to $238.7M, were sourced from SUN PHARMACEUTICAL INDUSTRIES LIMITED, with an additional $8.4M (3.4%) from SUN PHARMACEUTICAL INDUSTRIES LTD. This reliance on a single supplier for the majority of their imports indicates a preference for cost-effective generic medications, which are integral to their supply chain.

The importation of 5,230 unique finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, reflects a diverse formulation preference. This variety ensures the availability of multiple administration routes, catering to different patient needs and preferences. India's role as a leading producer of high-quality, affordable generic drugs aligns with Yusen Logistics' strategy to provide a broad spectrum of medications while maintaining cost efficiency.

The product mix and sourcing patterns of Yusen Logistics Benelux Belgium suggest a strategic positioning within the Belgian pharmaceutical market. The focus on essential medications across key therapeutic areas, combined with the importation of finished pharmaceutical formulations, indicates a primary engagement with retail pharmacies and hospital networks. By supplying a wide range of generic medications, Yusen Logistics supports healthcare providers in offering cost-effective treatment options to patients.

Additionally, the scale and diversity of their imports position Yusen Logistics as a significant player in the wholesale distribution sector. Their ability to supply large volumes of essential medications aligns with the needs of government tenders and large healthcare institutions seeking reliable and affordable pharmaceutical products. This comprehensive approach enables Yusen Logistics to effectively serve various segments of the Belgian healthcare market.

Given the current supplier concentration, opportunities for new Indian pharmaceutical exporters to collaborate with Yusen Logistics Benelux Belgium appear limited. Sun Pharmaceutical Industries Limited's substantial market share indicates a strong, established relationship, potentially leaving minimal room for additional suppliers. However, potential gaps may exist in therapeutic categories beyond the top three, or in niche products not currently supplied by existing partners. Identifying these specific areas could present entry points for new suppliers.

To engage with Yusen Logistics Benelux Belgium and the broader Belgian market, Indian pharmaceutical exporters must adhere to stringent quality and regulatory standards. Essential certifications include:

• Good Manufacturing Practice (GMP): Compliance with GMP standards, as recognized by the European Medicines Agency (EMA), is mandatory to ensure product quality and safety.

• European Union Good Distribution Practice (GDP): Adherence to GDP guidelines is crucial for maintaining product integrity throughout the supply chain.

• Product Registration: Medicinal products must be registered with the Federal Agency for Medicines and Health Products (FAMHP) in Belgium, necessitating comprehensive documentation and compliance with local regulations.

Additionally, obtaining a Certificate of Suitability (CEP) from the European Directorate for the Quality of Medicines (EDQM) can facilitate market entry by demonstrating compliance with European Pharmacopoeia standards.

Establishing a partnership with Yusen Logistics Benelux Belgium requires a strategic and methodical approach:

1. Market Analysis: Conduct thorough research to identify unmet needs within Yusen's product portfolio, focusing on therapeutic areas or products not currently supplied by existing partners.

2. Regulatory Compliance: Ensure all products meet EU regulatory requirements, including GMP and GDP certifications, and complete the necessary product registrations with FAMHP.

3. Direct Engagement: Initiate contact with Yusen Logistics through formal channels, presenting a well-prepared proposal that highlights your company's capabilities, compliance credentials, and the specific products you offer that align with their potential needs.

4. Tender Participation: Monitor for any tender opportunities issued by Yusen Logistics or associated pharmaceutical companies. Participating in these tenders can provide a structured pathway to demonstrate your offerings and establish credibility.

5. Distributor Partnerships: Consider collaborating with established distributors in Belgium who have existing relationships with Yusen Logistics. This can serve as an indirect route to supply products while navigating market entry challenges.

Building a relationship with Yusen Logistics Benelux Belgium is a long-term endeavor, requiring consistent engagement, adherence to regulatory standards, and a clear demonstration of value addition to their supply chain.